ANGPTL3, ANGPTL4, and ANGPTL8: Angiopoietin-like Proteins Regulating LPL, Triglycerides, and Dyslipidemia Including Evinacumab in Research

# ANGPTL3, ANGPTL4, and ANGPTL8: Angiopoietin-like Proteins Regulating LPL, Triglycerides, and Dyslipidemia Including Evinacumab in Research

The angiopoietin-like proteins ANGPTL3, ANGPTL4, and ANGPTL8 form a nutrient-sensing regulatory triad that coordinates lipoprotein lipase (LPL) activity across different tissues in response to fasting and feeding cycles. By inhibiting LPL in a compartment- and context-specific manner, these proteins determine the distribution of plasma triglyceride uptake between skeletal muscle (for oxidation) and white adipose tissue (for storage), providing a dynamic switch for fuel partitioning. The identification of naturally occurring loss-of-function variants in ANGPTL3 and ANGPTL4 as strongly cardioprotective in large human genetic studies, and the subsequent FDA approval of evinacumab (anti-ANGPTL3 monoclonal antibody) for homozygous familial hypercholesterolemia, has made this regulatory axis one of the most intensively pursued in lipid-cardiovascular medicine.

The Angiopoietin-like Protein Family

The angiopoietin-like proteins (ANGPTLs) comprise a family of 8 secreted glycoproteins (ANGPTL1-8) that share structural homology with angiopoietins (ANG1-4, which regulate vascular development via Tie1/Tie2 receptors), particularly an N-terminal coiled-coil domain and a C-terminal fibrinogen-related domain (FReD). Despite structural homology, ANGPTLs do not bind Tie receptors and have functions distinct from angiopoietins. Within the ANGPTL family, ANGPTL3, ANGPTL4, and ANGPTL8 form a functionally integrated regulatory unit specifically focused on lipoprotein metabolism.

ANGPTL3: Liver-Derived LPL Inhibitor and Cardiovascular Drug Target

Discovery and Biology

ANGPTL3 was identified by Conklin et al. (1999,) in a screen for proteins secreted by the liver. The human ANGPTL3 gene is located on chromosome 1p31.3 and encodes a 460-amino acid glycoprotein (mature form after signal peptide cleavage: 434 amino acids; ~75 kDa with glycosylation). ANGPTL3 is expressed exclusively in the liver under the control of the LXRα (liver X receptor α) transcription factor, making its expression sensitive to sterol status and glucose/lipid metabolism.

The molecular mechanism of ANGPTL3 action was established by Shimizugawa et al. (2002): ANGPTL3 directly inhibits lipoprotein lipase (LPL) through binding to the catalytic domain, with an IC₅₀ for LPL inhibition of approximately 10 nM. LPL is the primary enzyme responsible for hydrolyzing triglycerides in VLDL and chylomicrons at the vascular endothelium of heart, skeletal muscle, and adipose tissue, releasing fatty acids for cellular uptake. ANGPTL3 inhibition of LPL impairs triglyceride clearance, raising plasma TG.

Crucially, ANGPTL3 inhibits LPL primarily in the post-heparin plasma and in the intravascular compartment, though recent work has clarified that ANGPTL3 (in complex with ANGPTL8, see below) preferentially inhibits LPL in oxidative tissues (heart, skeletal muscle) during the fasting→fed transition.

Natural ANGPTL3 loss-of-function variants provide compelling human genetics evidence for cardiovascular benefit:

• •Families with homozygous ANGPTL3 loss-of-function (familial combined hypolipidemia, FHBL2) show dramatically low TG, LDL-C, HDL-C, and near-absence of coronary artery calcification
• •The Myocardial Infarction Genetics Consortium data showed that heterozygous ANGPTL3 loss-of-function carriers have 34% lower odds of coronary artery disease
• •Carriers of loss-of-function ANGPTL3 variants in the UK Biobank have lower all-cause mortality despite low HDL (challenging the HDL hypothesis)

Evinacumab: FDA-Approved ANGPTL3 Antibody

Evinacumab is a fully human monoclonal antibody (IgG4) targeting ANGPTL3, developed by Regeneron Pharmaceuticals. It binds ANGPTL3 with subnanomolar affinity and blocks LPL inhibition. Key clinical data:

Phase III ELIPSE HoFH trial (Ray et al., 2020,): In 65 patients with homozygous familial hypercholesterolemia (HoFH) — a severe genetic disorder causing LDL-C >300 mg/dL and early cardiovascular death — evinacumab 15 mg/kg IV every 4 weeks reduced LDL-C by 47.1% vs. placebo, even in patients already on maximally tolerated therapy including PCSK9 inhibitors and apheresis. Critically, evinacumab was effective in patients with null LDLR mutations (who are completely unresponsive to statins and PCSK9 inhibitors), because it acts through an LDLR-independent pathway.

Mechanism of LDL-C reduction: Unlike statins (which reduce LDL via LDLR upregulation) and PCSK9 inhibitors (which preserve LDLR), ANGPTL3 inhibition lowers LDL through a mechanism involving reduced VLDL secretion and possibly increased VLDL catabolism via LPL. The exact pathway by which ANGPTL3 inhibition reduces LDL (beyond TG reduction) involves modulation of VLDL-to-LDL conversion and is still being fully characterized.

FDA approval: Evinacumab received FDA approval in February 2021 for HoFH in adults and pediatric patients (≥12 years). It is the first ANGPTL3 inhibitor approved for human use. Additional indications (severe hypertriglyceridemia, mixed dyslipidemia) are under investigation.

ANGPTL4: Adipose-Derived Fasting LPL Inhibitor

Discovery and Biology

ANGPTL4 was independently discovered by Kersten et al. (2000, PMID: 10781483) and by Yoon et al. (2000, PMID: 10811899) as a PPARγ and PPARα target gene respectively. The human ANGPTL4 gene is on chromosome 19p13.3 and encodes a 406-amino acid protein. Unlike ANGPTL3, ANGPTL4 is expressed in multiple tissues, with highest expression in liver, adipose tissue, heart, and skeletal muscle.

ANGPTL4 is regulated by nutritional state in the opposite direction from ANGPTL3 in some tissues:

• •Fasting induces ANGPTL4 in adipose tissue (via PPARα/FGF21)
• •Feeding reduces adipose ANGPTL4

ANGPTL4 inhibits LPL by binding to the heparin-binding domain rather than the catalytic domain (different site from ANGPTL3). It does so by reversing LPL dimerization to the monomeric inactive form. ANGPTL4 is proposed to preferentially inhibit LPL in adipose tissue during fasting, thereby redirecting fatty acid uptake away from fat storage toward heart and skeletal muscle.

Proteolytic processing: The N-terminal coiled-coil domain of ANGPTL4 can be cleaved from the C-terminal FReD domain by proprotein convertases (furin, PCSK3). The N-terminal fragment is the LPL-inhibiting domain; the C-terminal fragment has been reported to influence cell adhesion, invasion, and angiogenesis.

ANGPTL4 loss-of-function in humans: The E40K variant (rs116843064) in ANGPTL4 is associated with lower TG, higher HDL, and reduced CAD risk (odds ratio ~0.65 for CAD per allele in the Myocardial Infarction Genetics study). Homozygous loss-of-function carriers have very low TG and higher adipose LPL activity.

Therapeutic development: Several pharmaceutical companies have developed anti-ANGPTL4 antibodies and antisense oligonucleotides (ASOs). However, clinical development has been complicated by reports in monkeys that ANGPTL4 loss-of-function causes mesenteric lymphadenopathy with lipid-laden macrophage infiltration — a potential safety liability that slowed development. This side effect has not been definitively reproduced in human genetic data (loss-of-function carriers do not appear to have lymphadenopathy), and development has continued.

ANGPTL8: The Nutrient-Sensitive Switch Protein

Discovery as the Metabolic Switch

ANGPTL8 (also known as lipasin, betatrophin, and RIFL — re-fed induced fat and liver gene) was identified in 2012-2013 by multiple groups. The human ANGPTL8 gene is on chromosome 19p13.2 and encodes a 198-amino acid protein, shorter than ANGPTL3/4 and lacking the N-terminal coiled-coil domain.

The naming history reflects confused discoveries: "betatrophin" was proposed by Yi et al. (2013,) based on the claim that ANGPTL8 promoted pancreatic β-cell proliferation — a claim that was subsequently NOT replicated, and the betatrophin hypothesis is now considered incorrect.

ANGPTL8 as a Molecular Switch in Lipoprotein Metabolism

The functional clarity of ANGPTL8 came from Quagliarini et al. (2012) and subsequent work by Dijk et al. (2016) and others, establishing ANGPTL8's role as a contextual switch:

Post-prandial state: Insulin and glucose increase ANGPTL8 in liver and adipose tissue.

• •ANGPTL8 forms a complex with ANGPTL3 and activates its LPL-inhibitory function in oxidative tissues (heart, skeletal muscle) → redirects TG from oxidative tissues to adipose
• •Simultaneously, ANGPTL8 interacts with ANGPTL4 and suppresses its function in adipose tissue → allows adipose LPL to remain active for fat storage
• •Net effect: post-prandial TG storage is directed to adipose tissue

Fasting state: ANGPTL8 declines.

• •ANGPTL3 alone (less potent without ANGPTL8 co-activation) inhibits LPL in circulation
• •ANGPTL4 is upregulated in adipose, inhibiting adipose LPL
• •Net effect: TG are redirected from adipose to heart/muscle for oxidative fuel

This ANGPTL3/ANGPTL8/ANGPTL4 triad thus constitutes a nutrient-sensing LPL regulation system that allocates dietary fat between storage and oxidation depending on feeding state.

ANGPTL8 plasma levels: Elevated in obesity, T2DM, and metabolic syndrome. ANGPTL8 serves as a biomarker of post-prandial/insulin state and metabolic dysfunction.

Unified Model: The ANGPTL3/4/8 Triad

This model positions the ANGPTL triad as a physiological fuel partitioning system that becomes dysregulated in metabolic disease, contributing to hypertriglyceridemia (elevated fasting TG when the system tilts toward impaired TG clearance).

Additional Biology Beyond LPL

ANGPTL3 and HDL: Beyond LPL inhibition, ANGPTL3 inhibits endothelial lipase (EL/LIPG), an enzyme that degrades HDL particles. ANGPTL3 inhibition (by evinacumab or natural variants) therefore also lowers HDL-C — a somewhat counterintuitive effect for a cardiovascular protective therapy. However, the lower HDL in ANGPTL3 deficiency appears to be functional HDL with normal efflux capacity, and the HDL lowering does not negate the cardiovascular benefit.

ANGPTL4 in cancer: The C-terminal FReD domain of ANGPTL4 promotes tumor angiogenesis and cancer cell invasion/migration in some contexts — ANGPTL4 expression in primary tumors has been associated with metastasis. This creates a dual role (metabolic protector, potential cancer promoter) that must be considered in therapeutic development.

ANGPTL3 in genetic hypertriglyceridemia: Beyond HoFH, ANGPTL3 gain-of-function variants have been identified in familial combined hyperlipidemia families. Anti-ANGPTL3 approaches (monoclonal antibodies, ASOs, siRNAs) are being evaluated for severe hypertriglyceridemia where pancreatitis risk is high.

ARO-ANG3 (Arrowhead/Novo Nordisk): An investigational RNA interference (RNAi) therapeutic targeting ANGPTL3 by liver-directed siRNA. Phase II data show ANGPTL3 reductions >90% and TG reductions >60%, with a monthly or quarterly dosing schedule. This could provide more convenient dosing than the IV evinacumab (every 4 weeks).

Research Tools and Experimental Systems

Current Research Frontiers

Evinacumab for beyond HoFH: Clinical trials of evinacumab for heterozygous FH (HeFH), mixed dyslipidemia, and hypertriglyceridemia are ongoing or planned, potentially expanding the approved indication substantially.

ANGPTL3 inhibition + statins + PCSK9 inhibitors: The triple combination (statin + PCSK9i + anti-ANGPTL3) is being evaluated in very high-risk cardiovascular patients who cannot achieve LDL goals with dual therapy alone. The LDLR-independent mechanism makes ANGPTL3 inhibition additive to both approaches.

ANGPTL4 development: Resolving the primate lymphadenopathy safety concern is critical for ANGPTL4 therapeutics. If this is species-specific (as human genetic data suggest), then ANGPTL4 inhibition could provide more selective adipose fat-storage modulation than ANGPTL3 inhibition.

ANGPTL8 biomarker: Plasma ANGPTL8 as a biomarker of insulin action and post-prandial state is being evaluated for metabolic disease monitoring. Its elevation in T2DM and metabolic syndrome may provide diagnostic information complementary to insulin and glucose measurements.

Nutrient-sensing LPL regulation in precision nutrition: Understanding how the ANGPTL3/4/8 system responds to different dietary patterns (low-carb, ketogenic, Mediterranean) and exercise could guide personalized nutrition recommendations aimed at optimizing TG clearance and fat partitioning.

Conclusion

The ANGPTL3/ANGPTL4/ANGPTL8 triad provides the molecular explanation for how plasma triglyceride levels are dynamically regulated across nutritional states, coordinating LPL activity between oxidative tissues (heart, muscle) and storage tissue (adipose) in response to insulin and nutrient signals. The compelling human genetic evidence — natural loss-of-function variants in ANGPTL3 and ANGPTL4 are consistently cardioprotective in large cohorts — drove successful drug development that led to FDA approval of evinacumab for HoFH, the first ANGPTL3 inhibitor in clinical use. The mechanism is LDLR-independent, making evinacumab uniquely valuable for patients with the most severe genetic LDL disorders who are unresponsive to conventional therapies. RNA interference approaches (ARO-ANG3) now offer the possibility of high-potency, infrequent-dosing ANGPTL3 suppression, potentially enabling wider clinical application. The remaining challenges include defining the full cardiovascular benefit of ANGPTL3 inhibition in general populations, resolving ANGPTL4 safety concerns for therapeutic development, and understanding how ANGPTL8-mediated post-prandial partitioning contributes to metabolic syndrome pathophysiology.

Key References

2. Shimizugawa T, Ono M, Shimamura M, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277(37):33742-33748. PMID: 12082093

3. Kersten S, Mandard S, Tan NS, et al. Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem. 2000;275(37):28488-28493. PMID: 10862772

4. Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA. 2012;109(48):19751-19756. PMID: 23150577

5. Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054-2063. PMID: 28385102

7. Dewey FE, Gusarova V, Dunbar RL, et al. Inactivating variants in ANGPTL4 and risk of coronary artery disease. N Engl J Med. 2016;374(12):1123-1133. PMID: 26933753

8. Dijk W, Kersten S. Regulation of lipoprotein lipase by Angptl4. Trends Endocrinol Metab. 2016;27(4):228-237. PMID: 26947381

9. Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377(3):222-232. PMID: 28538111

---

This article is intended for Research Use Only (RUO). The information provided describes laboratory research findings and does not constitute medical advice. ANGPTL3, ANGPTL4, and ANGPTL8 inhibitors including evinacumab are investigational or approved agents for specific indications. All research applications must comply with applicable institutional, local, and national regulations.